{"ticker": {"uuid": "bbfe1246-8883-4150-8d31-bba3b5dd0541", "symbol": "EQ", "name": "Equillium Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Piper Sandler Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $20", "summary": "Piper Sandler has initiated coverage on Equillium (EQ.US) with a Buy rating. The financial firm has set a target price of $20 for the company's stock. This indicates a positive outlook from Piper Sandler regarding Equillium's future performance.", "url": "https://www.moomoo.com/news/post/72868368/piper-sandler-initiates-equillium-equs-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-07-14T19:39:52", "published_display": "14 Jul 2026 19:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Piper Sandler initiates Equillium stock with overweight rating", "summary": "Piper Sandler has initiated coverage on Equillium Inc. (NASDAQ:EQ) with an overweight rating and a $20.00 price target, citing the company's lead asset EQ504 for ulcerative colitis. The firm highlights strong preclinical data for EQ504, a robust balance sheet, and significant ret", "url": "https://www.investing.com/news/analyst-ratings/piper-sandler-initiates-equillium-stock-with-overweight-rating-93CH-4787651", "source_name": "Investing.com", "published_at": "2026-07-13T09:10:52", "published_display": "13 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Initiates Coverage on Equillium With Overweight Rating, $20 Price Target", "summary": "Piper Sandler has initiated coverage on Equillium (NasdaqCM:EQ) with an Overweight rating and set a $20 price target. This announcement was made on July 13, 2026, at 08:15 am EDT. Equillium is a clinical-stage biotechnology company focused on developing novel therapeutics for sev", "url": "https://www.marketscreener.com/news/piper-sandler-initiates-coverage-on-equillium-with-overweight-rating-20-price-target-ce7f5edfd08ef724", "source_name": "marketscreener.com", "published_at": "2026-07-13T08:15:00", "published_display": "13 Jul 2026 08:15", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Equillium, Inc. Stocks", "summary": "This article lists Exchange Traded Funds (ETFs) that invest in Equillium, Inc. stocks, providing financial data for each fund including market value, weight, issuer, expense ratio, and performance. Two ETFs, iShares Microcap ETF (IWC) and Invesco NASDAQ Future Gen 200 ETF (QQQS),", "url": "https://www.tradingview.com/symbols/LSE-0A4D/etfs/", "source_name": "TradingView", "published_at": "2026-07-11T03:09:33", "published_display": "11 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium (EQ) Cantor Global Healthcare Conference 2025 Summary", "summary": "Equillium recently completed a $50 million financing round, with $30 million upfront, to advance its novel AhR modulator program, EQ504, targeting severe autoimmune and inflammatory diseases, particularly ulcerative colitis. Clinical development for EQ504 is expected to commence ", "url": "https://quartr.com/events/equillium-inc-eq-cantor-global-healthcare-conference-2025_FkRnvH1o", "source_name": "Quartr", "published_at": "2026-07-02T15:10:14", "published_display": "02 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $7", "summary": "Oppenheimer has reiterated its Buy rating for Equillium (EQ.US) and maintained its target price at $7.00. This suggests a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72262655/oppenheimer-maintains-equillium-equs-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-07-01T00:42:11", "published_display": "01 Jul 2026 00:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium, Inc.(NasdaqCM: EQ) added to Russell 3000E Index", "summary": "Equillium, Inc. (NasdaqCM: EQ), a clinical-stage biotechnology company, has been added to the Russell 3000E Index. The company is focused on developing novel therapeutics for severe autoimmune and inflammatory disorders, with a pipeline including immunomodulatory assets like EQ30", "url": "https://www.marketscreener.com/news/equillium-inc-nasdaqcm-eq-added-to-russell-3000e-index-ce7f5fdedd81f725", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T00:09:51", "published_display": "30 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium, Inc.(NasdaqCM: EQ) added to Russell Microcap Index", "summary": "Equillium, Inc. (NasdaqCM: EQ), a clinical-stage biotechnology company, has been added to the Russell Microcap Index, as well as the Russell 3000E Index and Russell 3000E Growth Benchmark. This inclusion highlights the company's growing market presence and visibility within the f", "url": "https://www.marketscreener.com/news/equillium-inc-nasdaqcm-eq-added-to-russell-microcap-index-ce7f5fdeda80f12d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:10:52", "published_display": "29 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Equillium, Inc. \u2013 NASDAQ:EQ", "summary": "This article provides financial data for Equillium, Inc. (NASDAQ: EQ), specifically focusing on its price-to-sales forward ratio. It appears to be a stub or a data point from a financial platform like TradingView, indicating that the specific period, value, and change information", "url": "https://www.tradingview.com/symbols/NASDAQ-EQ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T11:09:57", "published_display": "28 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Equillium, Inc. \u2013 NASDAQ:EQ", "summary": "This article focuses on the enterprise value to EBIT forward ratio for Equillium, Inc. (NASDAQ: EQ). It is a financial data point presented within the context of TradingView's platform, offering an overview of the company's financial metrics. The content is primarily a data displ", "url": "https://www.tradingview.com/symbols/NASDAQ-EQ/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:39:17", "published_display": "28 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Equillium, Inc. \u2013 NASDAQ:EQ", "summary": "The article focuses on the \"Price to book forward\" metric for Equillium, Inc. (NASDAQ: EQ) as presented on the TradingView platform. It indicates that the current market for EQ is closed with no trades. The content primarily lists financial and market data sources and disclaimers", "url": "https://www.tradingview.com/symbols/NASDAQ-EQ/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:39:35", "published_display": "28 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Equillium, Inc. \u2013 NASDAQ:EQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNQ3FUWk1sd19Sa25HVVN6VWVXOE1JOXladG5HWjZ2MzQ4SnFhcUtuMmlmYXBad0N3VE1MREl3dVV2RENVcVN0MkpERWxyTFRWQUo2RWtidXR5cV9hSlFOTk9MdXZuV24tTWZxSklPNVBKM1ZqMlE1NFB1RUNBZ25xVVJNbDF3SmR0dExxVm9pdTFTVHVMUmZPRFRid3FQdEE?oc=5", "source_name": "TradingView", "published_at": "2026-06-27T22:25:11+00:00", "published_display": "27 Jun 2026 22:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Equillium, Inc. \u2013 NASDAQ:EQ", "summary": "This article displays financial data for Equillium, Inc. (NASDAQ: EQ) related to its enterprise value to revenue forward metric. The content is presented within the TradingView platform, noting that markets are closed and showing no trades at the time of viewing. It appears to be", "url": "https://www.tradingview.com/symbols/NASDAQ-EQ/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:33:48", "published_display": "27 Jun 2026 21:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium, Inc. Actuals & Estimates (NASDAQ:EQ)", "summary": "This article provides financial actuals and estimates for Equillium, Inc. (EQ) traded on NASDAQ. It covers stock performance, analyst forecasts, historical prices, market capitalization, earnings reports, and other key financial metrics. The company's stock has seen a significant", "url": "https://www.tradingview.com/symbols/NASDAQ-EQ/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T13:10:53", "published_display": "25 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Inc (EQ) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Equillium Inc (EQ), detailing its price momentum, support and resistance levels, and key technical indicators. As of June 25, 2026, EQ has a price momentum score of 9.04, ranking high in its industry. The analysis suggests the stock i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eq/technical", "source_name": "TradingKey", "published_at": "2026-06-24T21:39:24", "published_display": "24 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "23% Of This Equillium Insider's Holdings Were Sold", "summary": "Insiders at Equillium (NASDAQ:EQ) have been net sellers over the last year, with Chief Scientific Officer & President Stephen Connelly selling US$724k worth of shares at US$3.16 per share. While the sale occurred around the current share price of US$2.99, indicating it's not a ma", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eq/equillium/news/23-of-this-equillium-insiders-holdings-were-sold", "source_name": "Simply Wall Street", "published_at": "2026-06-18T11:09:51", "published_display": "18 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Inc (EQ) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Equillium Inc (EQ) has an earnings forecast score of 9.25, ranking 7th in the Biotechnology & Medical Research industry. Analysts have an average price target of $2.50 for EQ, with most recommending a \"STRONG BUY\" rating. The company's previous quarter EPS was -$0.04, beating the", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eq/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T22:09:16", "published_display": "17 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Inc (EQ) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a financial overview of Equillium Inc (EQ), focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years and has no recorded stock splits. The report includes current stock performan", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eq/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:09:16", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Inc (EQ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Equillium Inc (EQ) by business segment and region. However, it explicitly states that the relevant data for such a breakdown has not yet been disclosed by the company. The page primarily serves as an overvie", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eq/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:09:16", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Grow More Confident In Equillium\u2019s (EQ) Lead Asset EQ504", "summary": "Equillium, Inc. (EQ) has seen increasing analyst confidence in its lead asset, EQ504, for ulcerative colitis. Leerink upgraded its rating to \"Outperform\" with a $6 price target, citing strong clinical and mechanistic validation and forecasting $1.5 billion in worldwide sales by 2", "url": "https://www.insidermonkey.com/blog/analysts-grow-more-confident-in-equilliums-eq-lead-asset-eq504-1779045/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-10T13:45:00", "published_display": "10 Jun 2026 13:45", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium (NASDAQ: EQ) Form 144: insider resale activity, 200,000-share sale noted", "summary": "Equillium, Inc. filed a Form 144 indicating proposed insider sales. The filing notes 30,975 shares \"to be sold\" and reported a past sale of 200,000 shares by Stephen Connelly on 06/04/2026, with Jefferies LLC listed as the broker. These shares are identified as \"Founders shares a", "url": "https://www.stocktitan.net/sec-filings/EQ/144-equillium-inc-sec-filing-c21c9a558975.html", "source_name": "Stock Titan", "published_at": "2026-06-06T01:08:49", "published_display": "06 Jun 2026 01:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Stephen Connelly Sells 230,975 Shares of Equillium Inc (EQ)", "summary": "Stephen Connelly, President and Chief Scientific Officer of Equillium Inc's subsidiary, sold 230,975 shares of Equillium Inc (EQ) on June 5, 2026. Following this transaction, Connelly now owns 762,025 shares. Equillium Inc, a biotechnology company, has seen 12 insider sells and 0", "url": "https://www.gurufocus.com/news/8903803/insider-sell-stephen-connelly-sells-230975-shares-of-equillium-inc-eq", "source_name": "GuruFocus", "published_at": "2026-06-05T22:08:49", "published_display": "05 Jun 2026 22:08", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Insider Sold Shares Worth $723,830, According to a Recent SEC Filing", "summary": "An insider at Equillium (EQ) sold shares worth $723,830, as revealed in a recent SEC filing. This transaction occurred on June 5, 2026, following another insider share sale worth $267,209 on June 1, 2026. Equillium is a clinical-stage biotechnology company focused on developing t", "url": "https://www.marketscreener.com/news/equillium-insider-sold-shares-worth-723-830-according-to-a-recent-sec-filing-ce7f5dd2d888f122", "source_name": "www.marketscreener.com", "published_at": "2026-06-05T21:09:20", "published_display": "05 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium COO Christine Zedelmayer sells $42,736 in stock", "summary": "Equillium's COO, Christine Zedelmayer, sold 14,584 shares of company stock for approximately $42,736, shortly after acquiring them through employee stock options. This sale was made under a Rule 10b5-1 trading plan. The timing coincides with significant stock performance gains an", "url": "https://m.investing.com/news/insider-trading-news/equillium-coo-christine-zedelmayer-sells-42736-in-stock-93CH-4729234?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-05T21:08:49", "published_display": "05 Jun 2026 21:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium (EQ) COO sells 14,584 shares after exercising stock options", "summary": "Equillium, Inc. (EQ) Senior Vice President and COO Christine Zedelmayer exercised stock options to acquire 14,584 shares and subsequently sold the same number of shares on the open market. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. After the sale", "url": "https://www.stocktitan.net/sec-filings/EQ/form-4-equillium-inc-insider-trading-activity-3134967c3a00.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:08:49", "published_display": "05 Jun 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium (NASDAQ: EQ) CSO Stephen Connelly sells 230,975 shares in open market", "summary": "Equillium's President and CSO, Stephen Connelly, sold a total of 230,975 shares of the company's common stock in open-market transactions on June 4 and June 5, 2026. The sales were executed at weighted average prices of $3.1638 and $2.9401 per share, respectively. Following these", "url": "https://www.stocktitan.net/sec-filings/EQ/form-4-equillium-inc-insider-trading-activity-82e70832bbdb.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:08:49", "published_display": "05 Jun 2026 21:08", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Equillium, Inc. SEC Filing", "summary": "This SEC filing for Equillium, Inc. (EQ) is a Form 144, indicating a notice of proposed sale of securities under Rule 144. The filing details the sale of 200,000 common shares by a founder, acquired at incorporation, with an aggregate market value of $632,760.00 through Jefferies", "url": "https://www.stocktitan.net/sec-filings/EQ/144-equillium-inc-sec-filing-48488534475f.html", "source_name": "Stock Titan", "published_at": "2026-06-04T21:38:57", "published_display": "04 Jun 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium(EQ) Stock Options Chain | Quotes & News", "summary": "This article provides the stock options chain for Equillium (EQ) and includes quotes and news related to the company. It serves as a resource for investors interested in EQ's options market.", "url": "https://www.moomoo.com/stock/EQ-US/options-chain?chain_id=Name1K9-3FXPhg.1kruc80&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A107,%22f%22%3A%22www.moomoo.com%2Fetfs%2FORCX-US%22%7D", "source_name": "Moomoo", "published_at": "2026-06-03T17:11:16", "published_display": "03 Jun 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Equillium, Inc. announced inducement grants of stock options and restricted stock units (RSUs) to three new non-executive employees. These grants were made outside of the company\u2019s 2021 Equity Incentive Plan as an inducement material to their employment, in accordance with Nasdaq", "url": "https://www.moomoo.com/news/post/70951372/equillium-reports-inducement-grants-under-nasdaq-listing-rule-5635-c", "source_name": "Moomoo", "published_at": "2026-06-03T12:40:10", "published_display": "03 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Insider Sold Shares Worth $267,209, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/equillium-insider-sold-shares-worth-081149881.html", "source_name": "MT Newswires", "published_at": "2026-06-01T08:11:49+00:00", "published_display": "01 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1", "summary": "", "url": "https://finance.yahoo.com/m/125a76c0-7742-3f3d-a813-c6fc5071ec7f/equillium-links-ahr.html", "source_name": "MarketBeat", "published_at": "2026-05-29T15:03:58+00:00", "published_display": "29 May 2026 15:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium to Participate in the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/equillium-participate-2026-jefferies-global-200500770.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T20:05:00+00:00", "published_display": "28 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Upgrades Equillium to Outperform From Market Perform, Adjusts PT to $6 From $1", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/leerink-partners-upgrades-equillium-outperform-103256215.html", "source_name": "MT Newswires", "published_at": "2026-05-28T10:32:56+00:00", "published_display": "28 May 2026 10:32", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/equillium-host-virtual-investor-event-200500168.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T20:05:00+00:00", "published_display": "20 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights", "summary": "", "url": "https://finance.yahoo.com/news/equillium-reports-first-quarter-2026-200100103.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T20:01:00+00:00", "published_display": "13 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Equillium, Inc. Grants Inducement Stock Options to New Employees Under 2024 Inducement Plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOSlJtUzNiaDIyNjQ0eFBIYV9odUNfNGFGcHI1TXVaQnFacXFiMHFCeFFmeHRpVWR4enU4cUpLYjBTdzBXbEJ3aTRwbm1zRTZPdVNxUFpnOGJsRU9neGtydXZXLTRXYTZlM2pYSjdUaEZ0SmFWT1JxVnBhUUJGWFpaTmttXzRYdUlWQ0ZZeEtWRVJCSmZvdXJ5aGVTZGlyZkpoRXhlLVZXanFhSFhUWWJRWEpQX0NiNmdvSGtBR1NsenJiOU1W?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here\u2019s What Roth Capital Thinks of Equillium (EQ) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPMDZBYVB4RGZueXRZT0UtVkczelY2UVMyT2NsSnQwN1JGenBuYXFPRkV1OTIxR0FMdklKV21zeWcxMFJFYkJHVGZKeFhuUEk0Qnk5c3dVeGlEYWxaUDFESXJrTWVUUFRQVUR1N0M3X1AydzJ5TnpETlQ4Rnl6S0hVX1dUZUhKUDFtUnpnZ3BNVFpvZW8zZVB3eW1NM2c4dw?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium, Inc. Common Stock (EQ) Stock Price Today: $2.96", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTFBtRVk5ZWRKWWRRTTBzbXZVTFdjWHlWR0hZSklBZU5QcGx0MS1HRWtZRFI2aHFxa1J6RUl2WWdaWFdHV3NkeTc0Mm9mc3laa0d1ZmY0RQ?oc=5", "source_name": "Gotrade", "published_at": "2026-03-17T17:59:34+00:00", "published_display": "17 Mar 2026 17:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Announces $35 Million Financing with RA Capital Management", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNc1pldXRKUVpRNzlEVVVkbTRhOXg3WnZJMzhZOUxYMjM4Q0gtUDNtR0JoMjNUZmVkWE1IbnVWTUFlenpsSEtRUkVCQk1KajljVTRLTXlYRHR0WmNsS2t4a09ZS2MxNG4ya2VhcUI5VFVyNjVMZGVtZnB6WnlncE1kc1ctcVhKRnBoQWNkQ3BLRjFYRWdBSHdWX2FYRk5tWTYwb1k2TjVGYndoS0dyZVZTalBzWkxYMjF1Tm1yMmxvTW1FUFpyWmxHc0VENmJUUmRYUnBYeER3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Equillium (EQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE90N05rRFdmcUlsZTVETUZrdXllZlRpbG42UjIyRlVQSTJUTk9NQkNXdUd6ZTl2U2owWmFENmo4SGhKZzliZXJIclZ0SUV6Q0d3akdWVzM4RFpDZmtjeGF6VVVRMXA2bEZzR0E?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-11-20T08:00:00+00:00", "published_display": "20 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxOT24tOEtiSWJTOXRmXzhiTXpDYkpLRjEybi03TGtXTU9ZYUJUcVh6M0FyWGdvOC1Dd3F3OVcxWjBQYmFuXzhoQkhiaVg3aTBSaHI2aWQ0SE9BckRHSFYyby13Tm5WTmxmS25RM1JKZjJ3YlVScnc2XzFsc2t6a2VJTjZNY1dvSUh0bTBZQkpyRXlYelFDSEZzSU9fdWRKRWpsZjZqZU1YQ2YxX0VScTByNzVtRlZjdm9Ec0lVbVJkVzNjMUJJREM5X21ZVHFibGR2eDgyMG5HVGpSY081emRuRDBFNzlUZEVXTU41V2Z0UU1xblMwempaMXg5aGpuQjA2VWtZLXhHbi1YOG1MMDNTWA?oc=5", "source_name": "Business Wire", "published_at": "2025-08-11T07:00:00+00:00", "published_display": "11 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium (EQ) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFBmRnN3Mi1zVmdwZVVDTDg1ZFl5R0FjWnpYbG1FUEllZU9zeHdyXzc1c0kyb3VyczZlMnY5My1BUTM1Q3Buazk4UFV6RlFQSzZQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:48:40+00:00", "published_display": "25 Apr 2025 01:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium (EQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTEFVX3lxTE00cWR6TW10SXVYYmVqRmx1cFNsM2k1MTlNQTNzZmFqWC1IQ05paE45ZXNaWmNlaXR0UWp6TlJYNThYd3dNaWtJY1RPTmk?oc=5", "source_name": "Zacks Investment Research", "published_at": "2008-09-26T21:47:07+00:00", "published_display": "26 Sep 2008 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Piper Sandler Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $20", "summary": "Piper Sandler has initiated coverage on Equillium (EQ.US) with a Buy rating. The financial firm has set a target price of $20 for the company's stock. This indicates a positive outlook from Piper Sandler regarding Equillium's future performance.", "url": "https://www.moomoo.com/news/post/72868368/piper-sandler-initiates-equillium-equs-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-07-14T19:39:52", "published_display": "14 Jul 2026 19:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler initiates Equillium stock with overweight rating", "summary": "Piper Sandler has initiated coverage on Equillium Inc. (NASDAQ:EQ) with an overweight rating and a $20.00 price target, citing the company's lead asset EQ504 for ulcerative colitis. The firm highlights strong preclinical data for EQ504, a robust balance sheet, and significant ret", "url": "https://www.investing.com/news/analyst-ratings/piper-sandler-initiates-equillium-stock-with-overweight-rating-93CH-4787651", "source_name": "Investing.com", "published_at": "2026-07-13T09:10:52", "published_display": "13 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Initiates Coverage on Equillium With Overweight Rating, $20 Price Target", "summary": "Piper Sandler has initiated coverage on Equillium (NasdaqCM:EQ) with an Overweight rating and set a $20 price target. This announcement was made on July 13, 2026, at 08:15 am EDT. Equillium is a clinical-stage biotechnology company focused on developing novel therapeutics for sev", "url": "https://www.marketscreener.com/news/piper-sandler-initiates-coverage-on-equillium-with-overweight-rating-20-price-target-ce7f5edfd08ef724", "source_name": "marketscreener.com", "published_at": "2026-07-13T08:15:00", "published_display": "13 Jul 2026 08:15", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Equillium, Inc. Stocks", "summary": "This article lists Exchange Traded Funds (ETFs) that invest in Equillium, Inc. stocks, providing financial data for each fund including market value, weight, issuer, expense ratio, and performance. Two ETFs, iShares Microcap ETF (IWC) and Invesco NASDAQ Future Gen 200 ETF (QQQS),", "url": "https://www.tradingview.com/symbols/LSE-0A4D/etfs/", "source_name": "TradingView", "published_at": "2026-07-11T03:09:33", "published_display": "11 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium (EQ) Cantor Global Healthcare Conference 2025 Summary", "summary": "Equillium recently completed a $50 million financing round, with $30 million upfront, to advance its novel AhR modulator program, EQ504, targeting severe autoimmune and inflammatory diseases, particularly ulcerative colitis. Clinical development for EQ504 is expected to commence ", "url": "https://quartr.com/events/equillium-inc-eq-cantor-global-healthcare-conference-2025_FkRnvH1o", "source_name": "Quartr", "published_at": "2026-07-02T15:10:14", "published_display": "02 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $7", "summary": "Oppenheimer has reiterated its Buy rating for Equillium (EQ.US) and maintained its target price at $7.00. This suggests a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72262655/oppenheimer-maintains-equillium-equs-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-07-01T00:42:11", "published_display": "01 Jul 2026 00:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium, Inc.(NasdaqCM: EQ) added to Russell 3000E Index", "summary": "Equillium, Inc. (NasdaqCM: EQ), a clinical-stage biotechnology company, has been added to the Russell 3000E Index. The company is focused on developing novel therapeutics for severe autoimmune and inflammatory disorders, with a pipeline including immunomodulatory assets like EQ30", "url": "https://www.marketscreener.com/news/equillium-inc-nasdaqcm-eq-added-to-russell-3000e-index-ce7f5fdedd81f725", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T00:09:51", "published_display": "30 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium, Inc.(NasdaqCM: EQ) added to Russell Microcap Index", "summary": "Equillium, Inc. (NasdaqCM: EQ), a clinical-stage biotechnology company, has been added to the Russell Microcap Index, as well as the Russell 3000E Index and Russell 3000E Growth Benchmark. This inclusion highlights the company's growing market presence and visibility within the f", "url": "https://www.marketscreener.com/news/equillium-inc-nasdaqcm-eq-added-to-russell-microcap-index-ce7f5fdeda80f12d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:10:52", "published_display": "29 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Equillium, Inc. \u2013 NASDAQ:EQ", "summary": "This article provides financial data for Equillium, Inc. (NASDAQ: EQ), specifically focusing on its price-to-sales forward ratio. It appears to be a stub or a data point from a financial platform like TradingView, indicating that the specific period, value, and change information", "url": "https://www.tradingview.com/symbols/NASDAQ-EQ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T11:09:57", "published_display": "28 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Equillium, Inc. \u2013 NASDAQ:EQ", "summary": "This article focuses on the enterprise value to EBIT forward ratio for Equillium, Inc. (NASDAQ: EQ). It is a financial data point presented within the context of TradingView's platform, offering an overview of the company's financial metrics. The content is primarily a data displ", "url": "https://www.tradingview.com/symbols/NASDAQ-EQ/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:39:17", "published_display": "28 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Equillium, Inc. \u2013 NASDAQ:EQ", "summary": "The article focuses on the \"Price to book forward\" metric for Equillium, Inc. (NASDAQ: EQ) as presented on the TradingView platform. It indicates that the current market for EQ is closed with no trades. The content primarily lists financial and market data sources and disclaimers", "url": "https://www.tradingview.com/symbols/NASDAQ-EQ/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:39:35", "published_display": "28 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Equillium, Inc. \u2013 NASDAQ:EQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNQ3FUWk1sd19Sa25HVVN6VWVXOE1JOXladG5HWjZ2MzQ4SnFhcUtuMmlmYXBad0N3VE1MREl3dVV2RENVcVN0MkpERWxyTFRWQUo2RWtidXR5cV9hSlFOTk9MdXZuV24tTWZxSklPNVBKM1ZqMlE1NFB1RUNBZ25xVVJNbDF3SmR0dExxVm9pdTFTVHVMUmZPRFRid3FQdEE?oc=5", "source_name": "TradingView", "published_at": "2026-06-27T22:25:11+00:00", "published_display": "27 Jun 2026 22:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Equillium, Inc. \u2013 NASDAQ:EQ", "summary": "This article displays financial data for Equillium, Inc. (NASDAQ: EQ) related to its enterprise value to revenue forward metric. The content is presented within the TradingView platform, noting that markets are closed and showing no trades at the time of viewing. It appears to be", "url": "https://www.tradingview.com/symbols/NASDAQ-EQ/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:33:48", "published_display": "27 Jun 2026 21:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium, Inc. Actuals & Estimates (NASDAQ:EQ)", "summary": "This article provides financial actuals and estimates for Equillium, Inc. (EQ) traded on NASDAQ. It covers stock performance, analyst forecasts, historical prices, market capitalization, earnings reports, and other key financial metrics. The company's stock has seen a significant", "url": "https://www.tradingview.com/symbols/NASDAQ-EQ/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T13:10:53", "published_display": "25 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Inc (EQ) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Equillium Inc (EQ), detailing its price momentum, support and resistance levels, and key technical indicators. As of June 25, 2026, EQ has a price momentum score of 9.04, ranking high in its industry. The analysis suggests the stock i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eq/technical", "source_name": "TradingKey", "published_at": "2026-06-24T21:39:24", "published_display": "24 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "23% Of This Equillium Insider's Holdings Were Sold", "summary": "Insiders at Equillium (NASDAQ:EQ) have been net sellers over the last year, with Chief Scientific Officer & President Stephen Connelly selling US$724k worth of shares at US$3.16 per share. While the sale occurred around the current share price of US$2.99, indicating it's not a ma", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eq/equillium/news/23-of-this-equillium-insiders-holdings-were-sold", "source_name": "Simply Wall Street", "published_at": "2026-06-18T11:09:51", "published_display": "18 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Inc (EQ) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Equillium Inc (EQ) has an earnings forecast score of 9.25, ranking 7th in the Biotechnology & Medical Research industry. Analysts have an average price target of $2.50 for EQ, with most recommending a \"STRONG BUY\" rating. The company's previous quarter EPS was -$0.04, beating the", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eq/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T22:09:16", "published_display": "17 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Inc (EQ) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a financial overview of Equillium Inc (EQ), focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years and has no recorded stock splits. The report includes current stock performan", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eq/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:09:16", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Inc (EQ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Equillium Inc (EQ) by business segment and region. However, it explicitly states that the relevant data for such a breakdown has not yet been disclosed by the company. The page primarily serves as an overvie", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eq/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:09:16", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Grow More Confident In Equillium\u2019s (EQ) Lead Asset EQ504", "summary": "Equillium, Inc. (EQ) has seen increasing analyst confidence in its lead asset, EQ504, for ulcerative colitis. Leerink upgraded its rating to \"Outperform\" with a $6 price target, citing strong clinical and mechanistic validation and forecasting $1.5 billion in worldwide sales by 2", "url": "https://www.insidermonkey.com/blog/analysts-grow-more-confident-in-equilliums-eq-lead-asset-eq504-1779045/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-10T13:45:00", "published_display": "10 Jun 2026 13:45", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium (NASDAQ: EQ) Form 144: insider resale activity, 200,000-share sale noted", "summary": "Equillium, Inc. filed a Form 144 indicating proposed insider sales. The filing notes 30,975 shares \"to be sold\" and reported a past sale of 200,000 shares by Stephen Connelly on 06/04/2026, with Jefferies LLC listed as the broker. These shares are identified as \"Founders shares a", "url": "https://www.stocktitan.net/sec-filings/EQ/144-equillium-inc-sec-filing-c21c9a558975.html", "source_name": "Stock Titan", "published_at": "2026-06-06T01:08:49", "published_display": "06 Jun 2026 01:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Stephen Connelly Sells 230,975 Shares of Equillium Inc (EQ)", "summary": "Stephen Connelly, President and Chief Scientific Officer of Equillium Inc's subsidiary, sold 230,975 shares of Equillium Inc (EQ) on June 5, 2026. Following this transaction, Connelly now owns 762,025 shares. Equillium Inc, a biotechnology company, has seen 12 insider sells and 0", "url": "https://www.gurufocus.com/news/8903803/insider-sell-stephen-connelly-sells-230975-shares-of-equillium-inc-eq", "source_name": "GuruFocus", "published_at": "2026-06-05T22:08:49", "published_display": "05 Jun 2026 22:08", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Insider Sold Shares Worth $723,830, According to a Recent SEC Filing", "summary": "An insider at Equillium (EQ) sold shares worth $723,830, as revealed in a recent SEC filing. This transaction occurred on June 5, 2026, following another insider share sale worth $267,209 on June 1, 2026. Equillium is a clinical-stage biotechnology company focused on developing t", "url": "https://www.marketscreener.com/news/equillium-insider-sold-shares-worth-723-830-according-to-a-recent-sec-filing-ce7f5dd2d888f122", "source_name": "www.marketscreener.com", "published_at": "2026-06-05T21:09:20", "published_display": "05 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium COO Christine Zedelmayer sells $42,736 in stock", "summary": "Equillium's COO, Christine Zedelmayer, sold 14,584 shares of company stock for approximately $42,736, shortly after acquiring them through employee stock options. This sale was made under a Rule 10b5-1 trading plan. The timing coincides with significant stock performance gains an", "url": "https://m.investing.com/news/insider-trading-news/equillium-coo-christine-zedelmayer-sells-42736-in-stock-93CH-4729234?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-05T21:08:49", "published_display": "05 Jun 2026 21:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium (EQ) COO sells 14,584 shares after exercising stock options", "summary": "Equillium, Inc. (EQ) Senior Vice President and COO Christine Zedelmayer exercised stock options to acquire 14,584 shares and subsequently sold the same number of shares on the open market. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. After the sale", "url": "https://www.stocktitan.net/sec-filings/EQ/form-4-equillium-inc-insider-trading-activity-3134967c3a00.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:08:49", "published_display": "05 Jun 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium (NASDAQ: EQ) CSO Stephen Connelly sells 230,975 shares in open market", "summary": "Equillium's President and CSO, Stephen Connelly, sold a total of 230,975 shares of the company's common stock in open-market transactions on June 4 and June 5, 2026. The sales were executed at weighted average prices of $3.1638 and $2.9401 per share, respectively. Following these", "url": "https://www.stocktitan.net/sec-filings/EQ/form-4-equillium-inc-insider-trading-activity-82e70832bbdb.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:08:49", "published_display": "05 Jun 2026 21:08", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Equillium, Inc. SEC Filing", "summary": "This SEC filing for Equillium, Inc. (EQ) is a Form 144, indicating a notice of proposed sale of securities under Rule 144. The filing details the sale of 200,000 common shares by a founder, acquired at incorporation, with an aggregate market value of $632,760.00 through Jefferies", "url": "https://www.stocktitan.net/sec-filings/EQ/144-equillium-inc-sec-filing-48488534475f.html", "source_name": "Stock Titan", "published_at": "2026-06-04T21:38:57", "published_display": "04 Jun 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium(EQ) Stock Options Chain | Quotes & News", "summary": "This article provides the stock options chain for Equillium (EQ) and includes quotes and news related to the company. It serves as a resource for investors interested in EQ's options market.", "url": "https://www.moomoo.com/stock/EQ-US/options-chain?chain_id=Name1K9-3FXPhg.1kruc80&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A107,%22f%22%3A%22www.moomoo.com%2Fetfs%2FORCX-US%22%7D", "source_name": "Moomoo", "published_at": "2026-06-03T17:11:16", "published_display": "03 Jun 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Equillium, Inc. announced inducement grants of stock options and restricted stock units (RSUs) to three new non-executive employees. These grants were made outside of the company\u2019s 2021 Equity Incentive Plan as an inducement material to their employment, in accordance with Nasdaq", "url": "https://www.moomoo.com/news/post/70951372/equillium-reports-inducement-grants-under-nasdaq-listing-rule-5635-c", "source_name": "Moomoo", "published_at": "2026-06-03T12:40:10", "published_display": "03 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Insider Sold Shares Worth $267,209, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/equillium-insider-sold-shares-worth-081149881.html", "source_name": "MT Newswires", "published_at": "2026-06-01T08:11:49+00:00", "published_display": "01 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1", "summary": "", "url": "https://finance.yahoo.com/m/125a76c0-7742-3f3d-a813-c6fc5071ec7f/equillium-links-ahr.html", "source_name": "MarketBeat", "published_at": "2026-05-29T15:03:58+00:00", "published_display": "29 May 2026 15:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium to Participate in the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/equillium-participate-2026-jefferies-global-200500770.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T20:05:00+00:00", "published_display": "28 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Upgrades Equillium to Outperform From Market Perform, Adjusts PT to $6 From $1", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/leerink-partners-upgrades-equillium-outperform-103256215.html", "source_name": "MT Newswires", "published_at": "2026-05-28T10:32:56+00:00", "published_display": "28 May 2026 10:32", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/equillium-host-virtual-investor-event-200500168.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T20:05:00+00:00", "published_display": "20 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights", "summary": "", "url": "https://finance.yahoo.com/news/equillium-reports-first-quarter-2026-200100103.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T20:01:00+00:00", "published_display": "13 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium, Inc. Grants Inducement Stock Options to New Employees Under 2024 Inducement Plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOSlJtUzNiaDIyNjQ0eFBIYV9odUNfNGFGcHI1TXVaQnFacXFiMHFCeFFmeHRpVWR4enU4cUpLYjBTdzBXbEJ3aTRwbm1zRTZPdVNxUFpnOGJsRU9neGtydXZXLTRXYTZlM2pYSjdUaEZ0SmFWT1JxVnBhUUJGWFpaTmttXzRYdUlWQ0ZZeEtWRVJCSmZvdXJ5aGVTZGlyZkpoRXhlLVZXanFhSFhUWWJRWEpQX0NiNmdvSGtBR1NsenJiOU1W?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What Roth Capital Thinks of Equillium (EQ) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPMDZBYVB4RGZueXRZT0UtVkczelY2UVMyT2NsSnQwN1JGenBuYXFPRkV1OTIxR0FMdklKV21zeWcxMFJFYkJHVGZKeFhuUEk0Qnk5c3dVeGlEYWxaUDFESXJrTWVUUFRQVUR1N0M3X1AydzJ5TnpETlQ4Rnl6S0hVX1dUZUhKUDFtUnpnZ3BNVFpvZW8zZVB3eW1NM2c4dw?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium, Inc. Common Stock (EQ) Stock Price Today: $2.96", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTFBtRVk5ZWRKWWRRTTBzbXZVTFdjWHlWR0hZSklBZU5QcGx0MS1HRWtZRFI2aHFxa1J6RUl2WWdaWFdHV3NkeTc0Mm9mc3laa0d1ZmY0RQ?oc=5", "source_name": "Gotrade", "published_at": "2026-03-17T17:59:34+00:00", "published_display": "17 Mar 2026 17:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Announces $35 Million Financing with RA Capital Management", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNc1pldXRKUVpRNzlEVVVkbTRhOXg3WnZJMzhZOUxYMjM4Q0gtUDNtR0JoMjNUZmVkWE1IbnVWTUFlenpsSEtRUkVCQk1KajljVTRLTXlYRHR0WmNsS2t4a09ZS2MxNG4ya2VhcUI5VFVyNjVMZGVtZnB6WnlncE1kc1ctcVhKRnBoQWNkQ3BLRjFYRWdBSHdWX2FYRk5tWTYwb1k2TjVGYndoS0dyZVZTalBzWkxYMjF1Tm1yMmxvTW1FUFpyWmxHc0VENmJUUmRYUnBYeER3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Equillium (EQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE90N05rRFdmcUlsZTVETUZrdXllZlRpbG42UjIyRlVQSTJUTk9NQkNXdUd6ZTl2U2owWmFENmo4SGhKZzliZXJIclZ0SUV6Q0d3akdWVzM4RFpDZmtjeGF6VVVRMXA2bEZzR0E?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-11-20T08:00:00+00:00", "published_display": "20 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxOT24tOEtiSWJTOXRmXzhiTXpDYkpLRjEybi03TGtXTU9ZYUJUcVh6M0FyWGdvOC1Dd3F3OVcxWjBQYmFuXzhoQkhiaVg3aTBSaHI2aWQ0SE9BckRHSFYyby13Tm5WTmxmS25RM1JKZjJ3YlVScnc2XzFsc2t6a2VJTjZNY1dvSUh0bTBZQkpyRXlYelFDSEZzSU9fdWRKRWpsZjZqZU1YQ2YxX0VScTByNzVtRlZjdm9Ec0lVbVJkVzNjMUJJREM5X21ZVHFibGR2eDgyMG5HVGpSY081emRuRDBFNzlUZEVXTU41V2Z0UU1xblMwempaMXg5aGpuQjA2VWtZLXhHbi1YOG1MMDNTWA?oc=5", "source_name": "Business Wire", "published_at": "2025-08-11T07:00:00+00:00", "published_display": "11 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium (EQ) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFBmRnN3Mi1zVmdwZVVDTDg1ZFl5R0FjWnpYbG1FUEllZU9zeHdyXzc1c0kyb3VyczZlMnY5My1BUTM1Q3Buazk4UFV6RlFQSzZQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:48:40+00:00", "published_display": "25 Apr 2025 01:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equillium (EQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTEFVX3lxTE00cWR6TW10SXVYYmVqRmx1cFNsM2k1MTlNQTNzZmFqWC1IQ05paE45ZXNaWmNlaXR0UWp6TlJYNThYd3dNaWtJY1RPTmk?oc=5", "source_name": "Zacks Investment Research", "published_at": "2008-09-26T21:47:07+00:00", "published_display": "26 Sep 2008 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 51, "sentiment_summary": {"positive": 14, "negative": 5, "neutral": 32, "score": 55, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 17.2, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 2.91, "latest_week": "2026-07-10", "one_week_move": 0.0, "four_week_move": 3.6, "twelve_week_move": 42.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.297469, "market_dynamics_buy_signal": false, "relative_strength": 50.661577, "fair_value_gap": 147.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.0588, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +3.6% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 55, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Market source", "count": 6}, {"label": "Stock Titan", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "www.marketscreener.com", "count": 3}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 6}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.0% over one week, +3.6% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Piper Sandler Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $20"}], "updated_at": "2026-07-16T00:36:06.842889+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}